Is Vanda Pharmaceuticals Stock a Good Investment?
Vanda Pharmaceuticals Investment Advice | VNDA |
- Examine Vanda Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Vanda Pharmaceuticals' leadership team and their track record. Good management can help Vanda Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Vanda Pharmaceuticals' business and its evolving consumer preferences.
- Compare Vanda Pharmaceuticals' performance and market position to its competitors. Analyze how Vanda Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Vanda Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Vanda Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Vanda Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Vanda Pharmaceuticals is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Very Small | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Vanda Pharmaceuticals Stock
Researching Vanda Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 77.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 0.54. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Vanda Pharmaceuticals recorded a loss per share of 0.19. The entity had not issued any dividends in recent years.
To determine if Vanda Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Vanda Pharmaceuticals' research are outlined below:
| Vanda Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| Vanda Pharmaceuticals has a strong financial position based on the latest SEC filings | |
| Over 77.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Stephen Ray Mitchell Sells 5,000 Shares of Vanda Pharmaceuticals Inc. Stock |
Vanda Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Vanda Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Vanda Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Vanda Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Vanda Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Vanda Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-10-28 | 2020-09-30 | 0.1 | 0.11 | 0.01 | 10 | ||
2017-05-02 | 2017-03-31 | -0.19 | -0.17 | 0.02 | 10 | ||
2015-11-03 | 2015-09-30 | -0.2 | -0.22 | -0.02 | 10 | ||
2022-11-02 | 2022-09-30 | 0.09 | 0.06 | -0.03 | 33 | ||
2022-02-23 | 2021-12-31 | 0.09 | 0.12 | 0.03 | 33 | ||
2021-07-28 | 2021-06-30 | 0.14 | 0.17 | 0.03 | 21 | ||
2020-02-25 | 2019-12-31 | 0.11 | 0.08 | -0.03 | 27 | ||
2014-02-13 | 2013-12-31 | -0.2 | -0.23 | -0.03 | 15 |
Know Vanda Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Vanda Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vanda Pharmaceuticals backward and forwards among themselves. Vanda Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Vanda Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Prudential Financial Inc | 2024-09-30 | 776.8 K | Connor Clark & Lunn Inv Mgmt Ltd | 2024-06-30 | 725.4 K | Federated Hermes Inc | 2024-09-30 | 716.8 K | Charles Schwab Investment Management Inc | 2024-09-30 | 596.2 K | D. E. Shaw & Co Lp | 2024-09-30 | 559.8 K | Nuveen Asset Management, Llc | 2024-06-30 | 526.8 K | Northern Trust Corp | 2024-09-30 | 501.2 K | Bridgeway Capital Management, Llc | 2024-09-30 | 419.5 K | Krensavage Asset Management, Llc | 2024-09-30 | 414.7 K | Blackrock Inc | 2024-06-30 | 8.1 M | Renaissance Technologies Corp | 2024-09-30 | 4 M |
Vanda Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 314.86 M.Market Cap |
|
Vanda Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Capital Employed | (0.02) | (0.03) |
Determining Vanda Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Vanda Pharmaceuticals is a good buy. For example, gross profit margin measures Vanda Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Vanda Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the presentation of Vanda Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Vanda Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Vanda Pharmaceuticals' management manipulating its earnings.
Evaluate Vanda Pharmaceuticals' management efficiency
Vanda Pharmaceuticals has return on total asset (ROA) of (0.0364) % which means that it has lost $0.0364 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0302) %, meaning that it created substantial loss on money invested by shareholders. Vanda Pharmaceuticals' management efficiency ratios could be used to measure how well Vanda Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At present, Vanda Pharmaceuticals' Return On Tangible Assets are projected to increase slightly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0, whereas Return On Capital Employed is forecasted to decline to (0.03). At present, Vanda Pharmaceuticals' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 226.3 M, whereas Other Current Assets are forecasted to decline to about 7.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 9.50 | 9.97 | |
| Tangible Book Value Per Share | 7.38 | 7.75 | |
| Enterprise Value Over EBITDA | (10.58) | (11.11) | |
| Price Book Value Ratio | 0.44 | 0.42 | |
| Enterprise Value Multiple | (10.58) | (11.11) | |
| Price Fair Value | 0.44 | 0.42 | |
| Enterprise Value | 115.7 M | 109.9 M |
Management at Vanda Pharmaceuticals focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Beta 0.767 |
Basic technical analysis of Vanda Stock
As of the 28th of November, Vanda Pharmaceuticals has the Risk Adjusted Performance of (0.03), coefficient of variation of (2,260), and Variance of 6.71. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vanda Pharmaceuticals, as well as the relationship between them.Vanda Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vanda Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vanda Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vanda Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Vanda Pharmaceuticals' Outstanding Corporate Bonds
Vanda Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Vanda Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Vanda bonds can be classified according to their maturity, which is the date when Vanda Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand Vanda Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Vanda Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.11) | |||
| Mean Deviation | 1.95 | |||
| Coefficient Of Variation | (2,260) | |||
| Standard Deviation | 2.59 | |||
| Variance | 6.71 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.25) | |||
| Total Risk Alpha | (0.53) | |||
| Treynor Ratio | (0.12) | |||
| Maximum Drawdown | 14.93 | |||
| Value At Risk | (3.67) | |||
| Potential Upside | 4.08 | |||
| Skewness | 0.3501 | |||
| Kurtosis | 1.13 |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.11) | |||
| Mean Deviation | 1.95 | |||
| Coefficient Of Variation | (2,260) | |||
| Standard Deviation | 2.59 | |||
| Variance | 6.71 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.25) | |||
| Total Risk Alpha | (0.53) | |||
| Treynor Ratio | (0.12) | |||
| Maximum Drawdown | 14.93 | |||
| Value At Risk | (3.67) | |||
| Potential Upside | 4.08 | |||
| Skewness | 0.3501 | |||
| Kurtosis | 1.13 |
Consider Vanda Pharmaceuticals' intraday indicators
Vanda Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Vanda Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 67680.04 | |||
| Daily Balance Of Power | 0.4773 | |||
| Rate Of Daily Change | 1.04 | |||
| Day Median Price | 5.2 | |||
| Day Typical Price | 5.2 | |||
| Price Action Indicator | 0.095 | |||
| Period Momentum Indicator | 0.21 |
Vanda Pharmaceuticals Corporate Filings
F4 | 18th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 7th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 24th of May 2024 An amendment to a previously filed Form 8-K | ViewVerify |
Vanda Stock media impact
Far too much social signal, news, headlines, and media speculation about Vanda Pharmaceuticals that are available to investors today. That information is available publicly through Vanda media outlets and privately through word of mouth or via Vanda internal channels. However, regardless of the origin, that massive amount of Vanda data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Vanda Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Vanda Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Vanda Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Vanda Pharmaceuticals alpha.
Vanda Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Vanda Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Vanda Pharmaceuticals Corporate Management
| Scott Howell | Chief Officer | Profile | |
| Mihael MD | President, Founder | Profile | |
| Kevin Moran | CFO VP | Profile | |
| Elizabeth Every | Head Affairs | Profile | |
| Joakim Wijkstrom | Chief Marketing Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vanda Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Vanda Stock refer to our How to Trade Vanda Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vanda Pharmaceuticals. If investors know Vanda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vanda Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.96) | Earnings Share (0.19) | Revenue Per Share 3.293 | Quarterly Revenue Growth 0.228 | Return On Assets (0.04) |
The market value of Vanda Pharmaceuticals is measured differently than its book value, which is the value of Vanda that is recorded on the company's balance sheet. Investors also form their own opinion of Vanda Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vanda Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vanda Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vanda Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Vanda Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Vanda Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vanda Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.